What is Digostics?
Digostics specializes in providing innovative home testing platforms, particularly for the oral glucose tolerance test (OGTT). Their solutions enable patients to conduct essential diabetes screening tests with laboratory-grade accuracy from their residences, thereby enhancing early detection and facilitating prompt clinical interventions. The company's patient-centric approach and focus on interoperability aim to empower both healthcare providers and individuals in more effective diabetes management, catering to those at risk for type 1, type 2, and gestational diabetes.
How much funding has Digostics raised?
Digostics has raised a total of $675K across 1 funding round:
Other Financing Round
$675K
Other Financing Round (2025): $675K, investors not publicly disclosed
What's next for Digostics?
The recent major strategic investment signals a pivotal phase for Digostics, likely enabling accelerated product development, market expansion, and enhanced operational capabilities. This enterprise-level funding context suggests a strategic focus on scaling its reach and solidifying its position within the competitive health technology sector, particularly in the realm of remote diagnostics and chronic disease management.
See full Digostics company page
